3.07
전일 마감가:
$3.00
열려 있는:
$2.99
하루 거래량:
594.59K
Relative Volume:
0.72
시가총액:
$424.53M
수익:
-
순이익/손실:
$-45.44M
주가수익비율:
-8.7714
EPS:
-0.35
순현금흐름:
$-42.28M
1주 성능:
+5.14%
1개월 성능:
+27.92%
6개월 성능:
+17.62%
1년 성능:
+227.71%
Compass Therapeutics Inc Stock (CMPX) Company Profile
명칭
Compass Therapeutics Inc
전화
617-500-8099
주소
80 GUEST STREET, BOSTON
CMPX을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
CMPX
Compass Therapeutics Inc
|
3.07 | 403.78M | 0 | -45.44M | -42.28M | -0.35 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-01 | 재개 | Raymond James | Outperform |
2025-04-02 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
2025-02-24 | 개시 | Guggenheim | Buy |
2025-02-19 | 개시 | Piper Sandler | Overweight |
2024-12-23 | 개시 | D. Boral Capital | Buy |
2024-11-15 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
2024-09-16 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
2023-01-31 | 개시 | Jefferies | Buy |
2023-01-27 | 개시 | Stifel | Buy |
2022-05-23 | 재개 | H.C. Wainwright | Buy |
2022-03-15 | 개시 | Ladenburg Thalmann | Buy |
2022-01-19 | 개시 | B. Riley Securities | Buy |
2021-12-22 | 개시 | Raymond James | Outperform |
2021-12-20 | 개시 | SVB Leerink | Outperform |
2021-12-15 | 개시 | Wedbush | Outperform |
모두보기
Compass Therapeutics Inc 주식(CMPX)의 최신 뉴스
What drives Compass Therapeutics Inc. stock priceExceptional portfolio growth - jammulinksnews.com
Compass Therapeutics Inc. Stock Analysis and ForecastFree Investment Case Studies - PrintWeekIndia
What analysts say about Compass Therapeutics Inc. stockRapid wealth accumulation - Autocar Professional
Is Compass Therapeutics Inc. stock a growth or value playHigh Return Setup Scanner - beatles.ru
Is Compass Therapeutics Inc. a good long term investmentConsistent high-yield stocks - jammulinksnews.com
What analysts say about Compass Therapeutics Inc. stock outlookFree Real-Time Market Predictions - beatles.ru
What makes Compass Therapeutics Inc. stock price move sharply10x Return With Managed Risk - Newser
Why Compass Therapeutics Inc. stock attracts strong analyst attentionFree Access to Investment Community - Newser
How Axsome Therapeutics Inc. stock performs during market volatilityMulti Bagger Alerts - Newser
How Compass Therapeutics Inc. stock performs during market volatilityBreakout Level Watch - Newser
Compass Therapeutics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Stifel reiterates Buy rating on Compass Therapeutics stock with $11 target - Investing.com Canada
Contrasting Compass Therapeutics (NASDAQ:CMPX) & Generation Bio (NASDAQ:GBIO) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of “Buy” by Brokerages - Defense World
Compass Therapeutics (CMPX) soars 4.01% on FDA Fast Track Designation - AInvest
Vontobel Holding Ltd. Invests $57,000 in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics: Promising Clinical Trials and Strategic Confidence Earn Buy Rating - AInvest
Compass Therapeutics (NASDAQ:CMPX) Upgraded at Raymond James Financial - Defense World
Compass Therapeutics: Raymond James reinstates Outperform rating, $9 PT. - AInvest
Compass Therapeutics, Inc.(NasdaqCM: CMPX) added to Russell 3000E Growth Index - MarketScreener
Compass Therapeutics Completes Phase 2 Study on CTX-009 for Metastatic Colorectal Cancer - TipRanks
Dow Jumps Over 200 Points; FactSet Research Shares Gain After Q3 Results - Benzinga
PD-1 and PD-L1 Inhibitors Competitor Landscape Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Compass Therapeutics, Aurigene Discovery Tech - The Globe and Mail
SG Americas Securities LLC Buys 545,767 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Acquired by Bank of America Corp DE - Defense World
Compass Therapeutics, Inc. (NASDAQ:CMPX) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Sells 48,021 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics Confirms Directors at Annual Meeting - TipRanks
Cholangiocarcinoma Market Booming Worldwide, Estimated to Reach USD 2,334.4 Mn by 2032 | Incyte CorporationSOUTHEAST - SOUTHEAST - NEWS CHANNEL NEBRASKA
Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist - Yahoo Finance
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | - GuruFocus
CMPX to Participate in Virtual Meeting Hosted by Piper Sandler | CMPX Stock News - GuruFocus
Two Sigma Advisers LP Cuts Stake in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Transition Metals (CVE:XTM) Shares Up 62.5% – Time to Buy? - Defense World
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Purchased by Two Sigma Advisers LP - Defense World
BNP Paribas Financial Markets Makes New $27,000 Investment in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
ProShare Advisors LLC Has $42,000 Position in Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Northern Trust Corp Sells 43,164 Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) - Defense World
Compass Therapeutics, Inc. (CMPX) Stock Analysis: A Biotech Gem with Over 500% Potential Upside - DirectorsTalk Interviews
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewswire
Insider Buying: Thomas Schuetz Acquires Additional Shares of Com - GuruFocus
Compass Therapeutics Inc (CMPX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):